000061313 001__ 61313
000061313 005__ 20190709135510.0
000061313 0247_ $$2doi$$a10.1080/14760584.2017.1324303
000061313 0248_ $$2sideral$$a98721
000061313 037__ $$aART-2017-98721
000061313 041__ $$aeng
000061313 100__ $$0(orcid)0000-0001-8644-120X$$aMarinova, Dessislava$$uUniversidad de Zaragoza
000061313 245__ $$aMTBVAC from discovery to clinical trials in tuberculosis-endemic countries
000061313 260__ $$c2017
000061313 5060_ $$aAccess copy available to the general public$$fUnrestricted
000061313 5203_ $$aIntroduction: BCG remains the only vaccine against tuberculosis (TB) in use today and despite its impressive global coverage, the nature of BCG protection against the pulmonary forms of TB remains subject to ongoing debate. Because of the limitations of BCG, novel TB vaccine candidates have been developed and several have reached the clinical pipeline. One of these candidates is MTBVAC, the first and only TB vaccine in the clinical pipeline to date based on live-attenuated Mycobacterium tuberculosis that has successfully entered clinical evaluation, a historic milestone in human vaccinology. Areas covered: This review describes development of MTBVAC from discovery to clinical development in high burden TB-endemic countries. The preclinical experiments where MTBVAC has shown to confer improved safety and efficacy over BCG are presented and the clinical development plans for MTBVAC are revealed. The search of all supportive literature in this manuscript was carried out via Pubmed. Expert commentary: Small experimental medicine trials in humans and preclinical efficacy studies with a strong immunological component mimicking clinical trial design are considered essential by the scientific community to help identify reliable vaccine-specific correlates of protection in order to support and accelerate community-wide efficacy trials of new TB vaccines.
000061313 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/BIO2014-5258P$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 643381-TBVAC2020$$9info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020
000061313 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000061313 590__ $$a4.271$$b2017
000061313 591__ $$aIMMUNOLOGY$$b43 / 155 = 0.277$$c2017$$dQ2$$eT1
000061313 592__ $$a1.551$$b2017
000061313 593__ $$aDrug Discovery$$c2017$$dQ1
000061313 593__ $$aPharmacology$$c2017$$dQ1
000061313 593__ $$aMolecular Medicine$$c2017$$dQ1
000061313 593__ $$aImmunology$$c2017$$dQ2
000061313 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000061313 700__ $$0(orcid)0000-0001-8841-6593$$aGonzalo-Asensio, Jesús$$uUniversidad de Zaragoza
000061313 700__ $$0(orcid)0000-0001-7897-9173$$aAguiló, Nacho$$uUniversidad de Zaragoza
000061313 700__ $$0(orcid)0000-0003-2993-5478$$aMartín, Carlos$$uUniversidad de Zaragoza
000061313 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología
000061313 7102_ $$11008$$2X$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cProy. investigación HQA
000061313 773__ $$g16, 6 (2017), 565-576$$pExpert rev. vaccines$$tExpert Review of Vaccines$$x1476-0584
000061313 8564_ $$s1617108$$uhttps://zaguan.unizar.es/record/61313/files/texto_completo.pdf$$yVersión publicada
000061313 8564_ $$s130198$$uhttps://zaguan.unizar.es/record/61313/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000061313 909CO $$ooai:zaguan.unizar.es:61313$$particulos$$pdriver
000061313 951__ $$a2019-07-09-11:51:40
000061313 980__ $$aARTICLE